Lataa...
Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth
Osteosarcoma (OS) is the most common form of primary malignant bone tumor and prevalent among children and young adults. Recently we have established a novel approach to bioengineering large quantity of microRNA-34a (miR-34a) prodrug for miRNA replacement therapy. This study is to evaluate combinati...
Tallennettuna:
| Julkaisussa: | Biochem Pharmacol |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4725324/ https://ncbi.nlm.nih.gov/pubmed/26518752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2015.10.015 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|